When the whole exceeds the sum of its parts. Squeezing greater cumulative benefit from cross-technology partnerships in bacterial infection
Loading...
Author (Corporation)
Publication date
2026
Type of student thesis
Course of study
Collections
Type
01A - Journal article
Editors
Editor (Corporation)
Supervisor
Parent work
International Journal of Infectious Diseases
Special issue
DOI of the original publication
Link
Related research data
Series
Series number
Volume
167
Issue / Number
Pages / Duration
108536
Patent number
Publisher / Publishing institution
Elsevier
Place of publication / Event location
Edition
Version
Programming language
Assignee
Practice partner / Client
Abstract
OBJECTIVES: Effective care for bacterial infections requires both new antibiotics (ABx) to address antimicrobial resistance (AMR) and appropriate diagnostics (Dx) to guide their use. Diagnostics are essential to identify pathogens, determine susceptibility, and support targeted prescribing, including ruling out unnecessary antibiotic use. However, diagnostics are undervalued in the current market, limiting their availability and integration with antibiotic development. To examine the interplay between antibiotics and diagnostics and assess the potential value of coordinated development and partnerships. METHODS: This paper analyses the antibiotic and diagnostic development landscape, focusing on market dynamics, regulatory frameworks, and collaboration models involving ABx developers, Dx developers, clinicians, and public-sector stakeholders. RESULTS: Antibiotics and diagnostics are rarely developed or introduced in parallel, and available diagnostics often fail to deliver treatment-focused or point-of-care-relevant results. This misalignment hampers the effective deployment of new antibiotics and weakens stewardship. Cross-technology partnerships can improve trial efficiency, enhance market valuation, and support more targeted antibiotic use. Key barriers include fragmented incentives, regulatory misalignment, and financial constraints. CONCLUSION: Better alignment between antibiotic and diagnostic development is critical to maximise clinical impact and support resistance monitoring. Public-sector support could help enable effective partnerships and improve patient outcomes.
Keywords
Subject (DDC)
Event
Exhibition start date
Exhibition end date
Conference start date
Conference end date
Date of the last check
ISBN
ISSN
1201-9712
1878-3511
1878-3511
Language
English
Created during FHNW affiliation
Yes
Strategic action fields FHNW
Publication status
Published
Review
peer-reviewed
Open access category
Gold
Citation
Saluzzo, F., Lindahl, O., Chindelevitch, L., Bachmann, T. T., Meinel, D., Papan, C., Mitsakakis, K., Gregori, V. D., Swe-Han, K. S., Krause, K. M., Trainor, B. W., Mutters, N. T., Özenci, V., Cirillo, D. M., & Morel, C. (2026). When the whole exceeds the sum of its parts. Squeezing greater cumulative benefit from cross-technology partnerships in bacterial infection. International Journal of Infectious Diseases, 167, 108536. https://doi.org/10.1016/j.ijid.2026.108536